We translate the inherent anti-inflammatory and pro-regenerative activities of Nanovesicles for tissue repair and the treatment of chronic inflammatory conditions.
Our focus is on naturally secreted EVs from human primary mesenchymal stromal cells (MSC), tendon derived progenitor cells, human platelets, and milk, as well as on artificially produced Cell-Derived Vesicles (CDVs), and hybrid Nanovesicles. We aim to uncover the mechanisms, components and parameters that appear critical for the successful clinical translation of bioactive Nanovesicles by:
- Developing robust and GMP-compliant manufacturing processes with defined critical quality attributes for anti-inflammatory / pro-regenerative Nanovesicles from different sources.
- Determining therapeutically relevant modes of action to guide Nanovesicle therapeutics development.
- Identifying confounding and enhancing co-factors and scaffolds for the optimization of Nanovesicle therapeutics.
- Profiling therapeutially relevant activities in cellular and animal models to enable stratification of clinically valuable Nanovesicle therapeutics candidates.
